188 related articles for article (PubMed ID: 27616880)
1. Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis.
Preusch MR; Rusnak J; Staudacher K; Mogler C; Uhlmann L; Sievers P; Bea F; Katus HA; Blessing E; Staudacher I
Drug Des Devel Ther; 2016; 10():2691-9. PubMed ID: 27616880
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.
Sievers P; Uhlmann L; Korkmaz-Icöz S; Fastner C; Bea F; Blessing E; Katus HA; Preusch MR
Drug Des Devel Ther; 2015; 9():3935-42. PubMed ID: 26251572
[TBL] [Abstract][Full Text] [Related]
3. Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice.
Ganbaatar B; Fukuda D; Salim HM; Nishimoto S; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Soeki T; Sata M
Atherosclerosis; 2018 Aug; 275():124-132. PubMed ID: 29902700
[TBL] [Abstract][Full Text] [Related]
4. Long-term administration of 3-deazaadenosine does not alter progression of advanced atherosclerotic lesions in apolipoprotein E-deficient mice.
Preusch MR; Bea F; Yang SH; Kreuzer J; Isermann B; Pedal I; Rosenfeld ME; Katus HA; Blessing E
J Cardiovasc Pharmacol; 2007 Aug; 50(2):206-12. PubMed ID: 17703138
[TBL] [Abstract][Full Text] [Related]
5. NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice.
Grootaert MOJ; Schrijvers DM; Van Spaendonk H; Breynaert A; Hermans N; Van Hoof VO; Takahashi N; Vandenabeele P; Kim SH; De Meyer GRY; Martinet W
Atherosclerosis; 2016 Sep; 252():166-174. PubMed ID: 27425215
[TBL] [Abstract][Full Text] [Related]
6. A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor.
Mao Y; Peng Y; Zeng Q; Cheng L; Wang B; Mao X; Meng K; Liu Y; Lian Y; Li D
PLoS One; 2015; 10(10):e0141464. PubMed ID: 26517374
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes.
Wang Z; Jiang Y; Liu N; Ren L; Zhu Y; An Y; Chen D
Atherosclerosis; 2012 Apr; 221(2):387-96. PubMed ID: 22305260
[TBL] [Abstract][Full Text] [Related]
8. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice.
Bea F; Kreuzer J; Preusch M; Schaab S; Isermann B; Rosenfeld ME; Katus H; Blessing E
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2787-92. PubMed ID: 16990551
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.
Zhou Q; Bea F; Preusch M; Wang H; Isermann B; Shahzad K; Katus HA; Blessing E
Mediators Inflamm; 2011; 2011():432080. PubMed ID: 21772662
[TBL] [Abstract][Full Text] [Related]
10. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice : dabigatran etexilate and atherosclerosis.
Kadoglou NP; Moustardas P; Katsimpoulas M; Kapelouzou A; Kostomitsopoulos N; Schafer K; Kostakis A; Liapis CD
Cardiovasc Drugs Ther; 2012 Oct; 26(5):367-74. PubMed ID: 22940777
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor suppresses oxidized low‑density lipoprotein‑induced endothelial cell apoptosis and alleviates atherosclerosis in ApoE‑/‑ mice via downregulation of PCSK9.
Xia X; Li J; Liang X; Zhang S; Liu T; Liu J; Arif M; Li G
Mol Med Rep; 2019 Mar; 19(3):1453-1462. PubMed ID: 30592271
[TBL] [Abstract][Full Text] [Related]
12. Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Aono J; Suzuki J; Iwai M; Horiuchi M; Nagai T; Nishimura K; Inoue K; Ogimoto A; Okayama H; Higaki J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1453-9. PubMed ID: 22460554
[TBL] [Abstract][Full Text] [Related]
13. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.
Blessing E; Preusch M; Kranzhöfer R; Kinscherf R; Marx N; Rosenfeld ME; Isermann B; Weber CM; Kreuzer J; Gräfe J; Katus HA; Bea F
Atherosclerosis; 2008 Aug; 199(2):295-303. PubMed ID: 18093593
[TBL] [Abstract][Full Text] [Related]
14. Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression.
Morris-Rosenfeld S; Blessing E; Preusch MR; Albrecht C; Bierhaus A; Andrassy M; Nawroth PP; Rosenfeld ME; Katus HA; Bea F
Eur J Clin Invest; 2011 Nov; 41(11):1164-71. PubMed ID: 21418204
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Orai1 Store-Operated Calcium Channel Prevents Foam Cell Formation and Atherosclerosis.
Liang SJ; Zeng DY; Mai XY; Shang JY; Wu QQ; Yuan JN; Yu BX; Zhou P; Zhang FR; Liu YY; Lv XF; Liu J; Ou JS; Qian JS; Zhou JG
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):618-28. PubMed ID: 26916730
[TBL] [Abstract][Full Text] [Related]
16. Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice.
Li D; Wang Y; Zhang L; Luo X; Li J; Chen X; Niu H; Wang K; Sun Y; Wang X; Yan Y; Chai W; Gartner TK; Liu J
Arterioscler Thromb Vasc Biol; 2012 Aug; 32(8):e81-9. PubMed ID: 22628428
[TBL] [Abstract][Full Text] [Related]
17. The intravenous injection of oxidized LDL- or Apolipoprotein B100--Coupled splenocytes promotes Th1 polarization in wildtype and Apolipoprotein E--Deficient mice.
Steinmetz M; Ponnuswamy P; Laurans L; Esposito B; Tedgui A; Mallat Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):306-11. PubMed ID: 26116775
[TBL] [Abstract][Full Text] [Related]
18. Genetic Evidence Supports a Major Role for Akt1 in VSMCs During Atherogenesis.
Rotllan N; Wanschel AC; Fernández-Hernando A; Salerno AG; Offermanns S; Sessa WC; Fernández-Hernando C
Circ Res; 2015 May; 116(11):1744-52. PubMed ID: 25868464
[TBL] [Abstract][Full Text] [Related]
19. Fibronectin Splicing Variants Containing Extra Domain A Promote Atherosclerosis in Mice Through Toll-Like Receptor 4.
Doddapattar P; Gandhi C; Prakash P; Dhanesha N; Grumbach IM; Dailey ME; Lentz SR; Chauhan AK
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2391-400. PubMed ID: 26427793
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.
Hara T; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Nishimoto S; Yagi S; Yamada H; Soeki T; Wakatsuki T; Shimabukuro M; Sata M
Atherosclerosis; 2015 Oct; 242(2):639-46. PubMed ID: 25817329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
